JP2009504614A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504614A5
JP2009504614A5 JP2008525578A JP2008525578A JP2009504614A5 JP 2009504614 A5 JP2009504614 A5 JP 2009504614A5 JP 2008525578 A JP2008525578 A JP 2008525578A JP 2008525578 A JP2008525578 A JP 2008525578A JP 2009504614 A5 JP2009504614 A5 JP 2009504614A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008525578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504614A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/065157 external-priority patent/WO2007017511A2/de
Publication of JP2009504614A publication Critical patent/JP2009504614A/ja
Publication of JP2009504614A5 publication Critical patent/JP2009504614A5/ja
Pending legal-status Critical Current

Links

JP2008525578A 2005-08-11 2006-08-08 アルツハイマー病の治療用化合物 Pending JP2009504614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017475 2005-08-11
PCT/EP2006/065157 WO2007017511A2 (de) 2005-08-11 2006-08-08 Verbindungen zur behandlung der alzheimer erkrankung

Publications (2)

Publication Number Publication Date
JP2009504614A JP2009504614A (ja) 2009-02-05
JP2009504614A5 true JP2009504614A5 (enExample) 2009-09-24

Family

ID=37719340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525578A Pending JP2009504614A (ja) 2005-08-11 2006-08-08 アルツハイマー病の治療用化合物

Country Status (5)

Country Link
US (1) US20100144681A1 (enExample)
EP (1) EP1919861A2 (enExample)
JP (1) JP2009504614A (enExample)
CA (1) CA2618481A1 (enExample)
WO (1) WO2007017511A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
EP2578212B1 (en) 2010-05-24 2016-07-06 Farmalider, S.A. Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses
US20120053200A1 (en) * 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス ノバ インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU652997B2 (en) * 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
DE69233109T2 (de) * 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
ES2265040T3 (es) * 2001-05-25 2007-02-01 Warner-Lambert Company Llc Composicion farmaceutica liquida.
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
AR039555A1 (es) * 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
AU2003206413A1 (en) * 2002-01-04 2003-07-24 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
RU2357962C2 (ru) * 2002-09-06 2009-06-10 Элан Фармасьютикалз, Инк. Пролекарственные производные 1,3-диамино-2-гидроксипропана
DE60329316D1 (de) * 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療のためのN−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
JP2007517781A (ja) * 2003-12-19 2007-07-05 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
EP1750719A2 (en) * 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050862A1 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病iiの治療のための置換エタン−1,2−ジアミン
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease

Similar Documents

Publication Publication Date Title
AU2014366361B2 (en) Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
JP2020523388A5 (enExample)
AR062299A1 (es) Derivados de bencimidazol
CA2445515A1 (en) Transcription factor modulating compounds and methods of use thereof
CY1113067T1 (el) Χρηση εκκριταγωγων αυξητικης ορμονης για τη διεγερση της κινητικοτητας του γαστρεντερικου συστηματος
EA200870517A1 (ru) Новые антагонисты мсн-рецепторов
RU2009110442A (ru) Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой
JP2009504612A5 (enExample)
JP2019526571A5 (enExample)
ZA200601324B (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity
WO2007097197A1 (ja) アミド誘導体またはその塩
CN103249414B (zh) 作为生长激素促泌素受体的生长素释放肽拮抗剂的具有改善受体活性和生物利用度性质的新三唑衍生物
JP2013540114A5 (enExample)
JP2017503030A5 (enExample)
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
JP2014510695A5 (enExample)
JP2009504613A5 (enExample)
JP2012522805A5 (enExample)
JP2017500321A5 (enExample)
JP2008534541A5 (enExample)
JP2009504611A5 (enExample)
US20110237602A1 (en) Method for treating schizophrenia and related diseases
JP2016536362A5 (enExample)
ES2537093T3 (es) Derivados de sulfamida utilizados como inhibidores de TAFIa
EP3362058B1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction